The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Shandong Hanfang Pharmaceutical Co., Ltd. 山東漢方製藥股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liabilit ...

Group 1 - The company reported a strong fiscal year 2025 with a 6% growth in revenue on an organic operational basis [2] - The bottom line also showed a 7% increase year-over-year, indicating strong financial discipline throughout the profit and loss statement [2] - The growth was characterized by a tale of two halves, with the first half achieving 9% growth, while the second half saw a decline to 6% due to various factors [2] Group 2 - There was noted weakness in the U.S. consumer market, which impacted overall performance [3]

Enanta Pharmaceuticals Conference Call Summary Company Overview - Enanta Pharmaceuticals is a drug discovery and development company based in Watertown, Massachusetts, specializing in small molecule drug discovery, particularly in infectious diseases and virology [2][3]. Key Products and Developments - Enanta has developed two protease inhibitors for hepatitis C in collaboration with AbbVie: VIEKIRA PAK and MAVYRET, the latter being the only 8-week cure for chronic and acute hepatitis C, curing between 1 and 2 million patients globally [3]. - Current focus includes developing treatments for respiratory syncytial virus (RSV), with no approved treatments available to date [3][4]. - Enanta has initiated programs targeting immunology, including: - **KIT**: Aiming to deplete mast cells for conditions like urticaria [8][39]. - **STAT6**: Targeting the IL-4, IL-13 pathway, with a goal to create an oral alternative to Dupixent [47]. - **MRGPRX2**: Aiming to address mast cell-driven diseases and potentially migraines [56]. RSV Programs - Enanta is developing two RSV molecules: - **Zelicapavir**: A replication inhibitor that has shown a reduction in symptom duration by about 7 days compared to placebo, with a 50% reduction in hospitalization rates observed in phase 2 studies [17][18]. - **EDP-323**: A potent viral polymerase inhibitor that demonstrated faster viral load reduction in challenge studies, potentially offering better efficacy [20][22]. - Phase 3 studies for Zelicapavir are planned, focusing on high-risk adult populations [14]. Immunology Programs - The first immunology program targeting KIT is on track for an IND filing in Q1 and phase 1 data in Q4 [40]. - The STAT6 program is expected to file for IND in the second half of the year [54]. - MRGPRX2 is in prototype optimization, with plans to have a candidate ready in the second half of the year [60]. Financial Position - Enanta reported $242 million in cash at the end of the last quarter, providing a runway into fiscal 2029 [61]. Strategic Considerations - Enanta is considering partnerships for its RSV products, weighing the timing of partnerships against the potential value generated from phase 3 data [31][32]. - The company aims to maintain a leadership position in RSV treatment while exploring the potential of EDP-323 as a next-generation option [25][27]. Conclusion - Enanta Pharmaceuticals is actively advancing its pipeline in both virology and immunology, with significant potential in treating RSV and mast cell-related diseases. The company is well-capitalized to support its clinical programs and is strategically evaluating partnership opportunities to maximize the commercial potential of its assets [61].

Summary of Conference Call Company and Industry - **Company**: Exelixis - **Industry**: Oncology, specifically focusing on renal cell carcinoma (RCC) and other cancer treatments Key Points and Arguments ASCO GU Conference Insights - Discussion centered around the results from the LITESPARK-011 trial for belzutifan and lenvatinib in second-line RCC, which showed a progression-free survival (PFS) benefit but lacked a statistically significant overall survival (OS) benefit at the second interim analysis [3][6] - The conversation among clinicians is shifting towards whether to combine therapies or sequence them, with LITESPARK-011 data aligning with this discussion [6][8] Treatment Dynamics - The overall PFS benefit from TKI monotherapy followed by belzutifan monotherapy is comparable to the data seen in previous studies, indicating a sequential treatment approach [7] - Incremental use of Cabometyx-nivolumab in the front line is anticipated as patients who receive lenvatinib and belzutifan in the second line are unlikely to receive lenvatinib first line [8] Quality of Life and Toxicity - Concerns were raised regarding the adverse events associated with the combination therapies, particularly hypoxia and cardiac dysfunction, which could complicate patient management [14][15] - The sequential treatment approach offers a "TKI break" for patients who have been on TKI therapies for extended periods, which is viewed positively by both patients and clinicians [15][17] Collaboration with Merck - The LITESPARK-033 trial is expected to define the standard of care for patients who have received prior adjuvant pembrolizumab, with an emphasis on understanding the treatment landscape in 2030 and beyond [20][21] - The collaboration aims to explore the potential of zanzalintinib as a next-generation TKI in combination with belzutifan [20][29] Non-Clear Cell RCC - The STELLAR-304 trial aims to establish a new standard of care for non-clear cell RCC, which constitutes 15%-20% of RCC cases, by providing robust evidence through a large randomized study [36][37] - The goal is to demonstrate a significant benefit across response rates, PFS, and ideally OS, compared to existing treatments [41] CRC and STELLAR-303 Trial - The STELLAR-303 trial for zanzalintinib and Tecentriq has shown a survival advantage over current standard care, which is expected to provide patients with access to checkpoint inhibitors [53][54] - The trial results indicate a robust response across various patient demographics, including those with liver metastases, which historically have shown poor prognosis [56][60] Future Guidance - The company anticipates a 10%-12% growth year-over-year by 2026, driven by continued momentum in the RCC base business and growth in the MET business [73] Other Important Insights - The competitive landscape in oncology is dynamic, with multiple trials ongoing that could influence treatment paradigms [26] - The differences in patient populations between early-phase and later-phase trials can significantly impact outcomes, highlighting the need for robust data [27][28] - The pharmacokinetic profile of zanzalintinib, with a shorter half-life compared to Cabometyx, is expected to enhance its usability in clinical practice [49]

Core Viewpoint - Roche's persevERA trial has failed, but the frontline opportunity for palazestrant is not considered eliminated by H.C. Wainwright [1] Summary by Relevant Categories Trial Outcomes - The persevERA trial results are described as "disappointing" [1] - The failure of the persevERA trial is not seen as a complete readthrough to Olema Oncology's OPERA-02 trial [1] Investment Perspective - H.C. Wainwright maintains a Buy rating on Olema shares, indicating confidence in the company's prospects despite the trial outcome [1] - The analyst suggests that differences in combination agents could favor the OPERA-02 trial, which is evaluating palazestrant plus ribociclib [1]

Mirum Pharmaceuticals Conference Call Summary Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease medicines, with a strategy centered on developing high-impact therapies for patients with rare diseases [4][5] Financial Performance - **Revenue Guidance**: Expected top line revenue for 2026 is between $630 million and $650 million, reflecting strong performance across three approved medicines [5][29] - **Growth Drivers**: The company anticipates four pivotal readouts over the next 18 months, indicating a pivotal year for growth [5][46] Product Pipeline and Commercial Opportunities LIVMARLI - **Indications**: Approved for Alagille syndrome and PFIC, with ongoing expansion into additional indications through the EXPAND study [8][30] - **Mechanism**: LIVMARLI reduces circulating bile acid levels, significantly alleviating symptoms such as pruritus in patients [8][9] - **Market Dynamics**: Steady growth in Alagille syndrome patient starts; PFIC adoption is dynamic due to increased genetic testing [10][13] - **Sales Growth**: LIVMARLI sales are expected to contribute significantly to the overall revenue, with projections indicating it could become a billion-dollar brand [45][94] Cholbam and CTEXLI - **Sales Performance**: Revenue for Cholbam and CTEXLI has grown to over $160 million, driven by increased awareness and diagnosis efforts [23][24] - **Market Strategy**: Focus on both raising awareness and identifying new patients for these rare conditions [24][26] Brelovitug - **Indication**: Targeting Hepatitis D, a rare and progressive liver disease with significant unmet need [52] - **Clinical Data**: Phase 2 data showed promising results, with a 100% virologic response at 48 weeks [57] - **Enrollment**: Rapid enrollment in registration studies indicates strong interest and potential for success [58] Volixibat - **Indications**: Targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) [78][87] - **Unique Approach**: Using pruritus as a primary endpoint for PSC, which has no approved therapies, represents a novel strategy [78][79] - **Market Potential**: Approximately 30,000 PSC patients in the U.S., with two-thirds experiencing pruritus, indicating a substantial launch population [81][83] Strategic Focus and Future Outlook - **Investment Strategy**: The company aims to balance investments in pipeline development while maintaining a positive cash flow position [98] - **Market Position**: Mirum expects to have a competitive edge in the PSC market due to the lack of approved therapies, allowing for a strong market presence for several years [96][94] - **Long-term Vision**: The company is focused on building value through new medicines and disciplined business development efforts [98][99] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a robust pipeline and strong commercial performance. The focus on rare diseases and innovative treatment approaches, combined with a solid financial outlook, presents a compelling investment opportunity.

Vertex Pharmaceuticals Conference Call Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Date**: March 10, 2026 - **Key Focus**: Discussion on company goals, product pipeline, and financial outlook Core Industry Insights 1. Company Goals for 2026 - Extend leadership in Cystic Fibrosis (CF) - Accelerate commercial diversification, particularly with DRNAvx and CASGEVY - Advance a broad pipeline with five ongoing Phase 3 trials - Deliver consistent financial results with revenue guidance of **$12.95 billion to $13.1 billion**, indicating **8%-9% growth** [7][8] 2. Product Pipeline and Efficacy Data - **POVI (povotazacet)**: - Recent data showed a **52% reduction in UPCR** at 36 weeks compared to baseline and a **50% reduction relative to placebo** [9] - Secondary endpoints showed a **77% reduction in Gd-IgA1 antibodies** and an **85% resolution rate in hematuria** [9] - Safety profile was strong with no serious adverse events (SAEs) related to POVI and no deaths in the trial [10] - Filing for regulatory approval expected by the end of March 2026 [11] 3. Commercialization Strategy - POVI is positioned as a potential best-in-class product due to its efficacy, safety, and convenient dosing [30] - The company is gearing up for a launch, having started planning in mid-2025 [31] 4. Growth Prospects - Continued growth in CF expected, with ongoing launches of ALYFTREK in the U.S. and internationally [22] - Anticipated tripling of JOURNAVX prescriptions in 2026, with coverage for approximately **200 million lives** [23][58] - Non-CF products like CASGEVY and JOURNAVX expected to become multibillion-dollar businesses [24][25] 5. Financial Outlook - Operating margins maintained in the low-to-mid **40% range** despite ongoing investments in the pipeline [24] - Investments in five Phase 3 trials and commercial organization for new products are expected to drive growth [24] Additional Important Insights 1. Competitive Landscape - Comparison with competitors like ATSUCA, noting that their data is at a later time point (week 40) [13] - Emphasis on the real-world population in the study, with a significant time from diagnosis to enrollment [19] 2. Future Data Releases - Additional data from ongoing trials will be released at appropriate times, with a focus on maintaining transparency with stakeholders [12] 3. Patient Support Programs - Medicare patients currently have access to JOURNAVX through a patient support program until formal coverage is secured [61][64] 4. Upcoming Milestones - Phase 3 results for DPN expected in late 2026 or early 2027 [26] - VX-828 Phase 1b data anticipated in the second half of 2026 [70][74] 5. CASGEVY Progress - Positive progress noted with over **300 patients** starting treatment in 2025, with expectations for continued growth in 2026 [76] This summary encapsulates the key points discussed during the Vertex Pharmaceuticals conference call, highlighting the company's strategic goals, product pipeline advancements, and financial outlook.

Group 1 - Orion Corporation has reported a transaction involving shares by Mikko Kemppainen, a senior manager, who received a share-based incentive of 3,685 shares at a unit price of 0 EUR on March 10, 2026 [1] - The transaction is categorized as an initial notification under the Market Abuse Regulation (EU) No 596/2014 [1] - The aggregated transaction details indicate a volume-weighted average price of 0 EUR for the shares involved [1] Group 2 - Orion Pharma, a subsidiary of Orion Corporation, is a Nordic pharmaceutical company with over a century of experience in developing, manufacturing, and marketing pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,890 million in 2025 and employs approximately 4,000 professionals globally [2] - Orion Pharma focuses on key therapy areas such as oncology and pain, with proprietary products aimed at treating cancer, respiratory diseases, and neurological diseases [2]

Core Insights - Bristol Myers Squibb (BMY) reported positive interim results from the late-stage SUCCESSOR-2 study, evaluating mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma (RRMM) patients [1][3] Group 1: Study Results - The SUCCESSOR-2 trial demonstrated that oral mezigdomide combined with carfilzomib and dexamethasone significantly improved progression-free survival compared to carfilzomib and dexamethasone alone in RRMM patients [3][10] - This study marks the first positive phase III trial for mezigdomide and the second successful phase III study for BMY's CELMoD program, reinforcing confidence in the company's targeted protein degradation platform [4][10] Group 2: Market Context - Despite advancements in treatment, multiple myeloma remains incurable, leading to strong demand for new therapies, particularly those effective after prior treatments [5] - Mezigdomide is designed to be more effective than earlier immunomodulatory drugs, potentially offering a convenient oral treatment option for patients previously treated with therapies like anti-CD38 antibodies and lenalidomide [6] Group 3: Company Strategy - BMY is looking to diversify its portfolio as its legacy drugs, such as Revlimid, face generic competition, which pressures revenue growth [7] - The successful development of mezigdomide could significantly boost the company's position in the market [7][10] - BMY's targeted protein degradation platform includes various investigational approaches aimed at tackling disease-driving proteins previously considered difficult to target [8] Group 4: Future Prospects - Patients in the SUCCESSOR-2 study will continue to be monitored for overall survival and long-term safety outcomes, with data to be presented at future medical meetings [4] - Mezigdomide is also being evaluated in other combinations in ongoing phase III studies, indicating a robust pipeline for BMY [9]

Core Insights - Teva Pharmaceuticals had a significant year in 2025, marked by substantial financial achievements and advancements in its pipeline [2]. Group 1 - Richard Francis serves as the President and CEO of Teva Pharmaceuticals, with Eli Kalif, Chris Stevo, and Sanjeev Sharma representing the Investor Relations team [1]. - The presentation is part of a conference hosted by Barclays Bank, indicating a focus on investor engagement and communication [1][3].